Granules India Limited
NSE: GRANULES BSE: GRANULES
NSE
532.80
-1.55 (-0.29%)
Prev Close
534.35
Open Price
535.45
Volume
694,448
Today Low / High
529.05 / 542
52 WK Low / High
422 / 628
Range
506 - 559
BSE
532.00
-2.45 (-0.46%)
Prev Close
534.45
Open Price
530.55
Volume
51,427
Today Low / High
529.05 / 541.6
52 WK Low / High
412.05 / 627.45
Range
505 - 559
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 532.8 (target range: 506 - 559), reflecting a change of -1.55 (-0.29007%). On the BSE, it is listed at 532 (target range: 505 - 559), showing a change of -2.45 (-0.45842%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
12 Sep
529.30
0.95%
11 Sep
522.50
0.69%
10 Sep
525.00
-0.07%
09 Sep
523.20
0.36%
08 Sep
513.40
1.14%
05 Sep
513.00
-0.31%
04 Sep
520.00
-1.38%
03 Sep
508.50
1.96%
02 Sep
515.80
-1.55%
01 Sep
494.00
4.41%
29 Aug
470.00
4.73%
28 Aug
474.00
-1.42%
26 Aug
459.00
2.29%
25 Aug
460.95
-0.05%
22 Aug
462.10
-0.78%
21 Aug
461.35
0.14%
20 Aug
458.00
0.73%
19 Aug
461.35
-0.72%
18 Aug
464.95
-0.77%
Granules India Limited Graph
Granules India Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Granules India Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 532.80, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 532.00 | 537.32 | 483.59 - 591.05 |
| 542.64 | 434.11 - 651.17 | ||
| 547.96 | 383.57 - 712.35 | ||
| Bearish Scenario | 532.00 | 526.68 | 474.01 - 579.35 |
| 521.36 | 417.09 - 625.63 | ||
| 516.04 | 361.23 - 670.85 |
Overview of Granules India Limited
ISIN
INE101D01020
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
1,507,414
Market Cap
129,656,821,400
Last Dividend
1.5
Official Website
IPO Date
2005-06-20
DCF Diff
-11.50
DCF
546
Financial Ratios Every Investor Needs
Stock Dividend of GRANULES
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-31 | July 31, 25 | 1.5 | 1.5 | 2025-07-31 | 2025-09-06 | |
| 2024-07-30 | July 30, 24 | 1.5 | 1.5 | 2024-07-30 | 2024-09-05 | |
| 2023-08-03 | August 03, 23 | 1.5 | 1.5 | 2023-08-03 | 2023-09-08 | |
| 2022-07-19 | July 19, 22 | 0.75 | 0.75 | 2022-07-20 | 2022-08-25 | |
| 2022-02-17 | February 17, 22 | 0.25 | 0.25 | 2022-02-18 | 2022-03-10 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 4,481.61 Cr | 2,611.00 Cr | 1,870.60 Cr | 0.4174 | 0.00 Cr | 146.05 Cr | 719.74 Cr | 501.52 Cr | 20.68 | 988.91 Cr | 0.1119 |
| 2024-03-31 | 4,506.37 Cr | 2,130.71 Cr | 2,375.66 Cr | 0.5272 | 198.56 Cr | 85.13 Cr | 652.83 Cr | 405.31 Cr | 16.73 | 826.32 Cr | 0.0899 |
| 2023-03-31 | 4,511.92 Cr | 2,307.29 Cr | 2,204.63 Cr | 0.4886 | 116.38 Cr | 73.88 Cr | 782.04 Cr | 516.60 Cr | 21.05 | 927.60 Cr | 0.1145 |
| 2022-03-31 | 3,727.17 Cr | 1,958.90 Cr | 1,768.27 Cr | 0.4744 | 142.96 Cr | 51.44 Cr | 574.62 Cr | 412.76 Cr | 16.65 | 739.84 Cr | 0.1107 |
| 2021-03-31 | 3,196.03 Cr | 1,455.00 Cr | 1,741.03 Cr | 0.5447 | 100.16 Cr | 37.56 Cr | 727.57 Cr | 549.46 Cr | 22.05 | 882.11 Cr | 0.1719 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 596.38 Cr | 6,252.56 Cr | 2,536.98 Cr | 3,715.5780 Cr | 1,454.76 Cr | 858.38 Cr | 1,342.82 Cr | 2,654.37 Cr | 0.00 Cr | 0.00 Cr | 23.08 Cr | 2,003.1610 Cr |
| 2024-03-31 | 381.10 Cr | 5,520.98 Cr | 2,295.44 Cr | 3,225.5440 Cr | 1,315.06 Cr | 933.96 Cr | 1,300.55 Cr | 2,259.78 Cr | 17.84 Cr | 0.00 Cr | 21.52 Cr | 2,082.2930 Cr |
| 2023-03-31 | 291.56 Cr | 4,904.56 Cr | 2,069.66 Cr | 2,834.9090 Cr | 1,136.24 Cr | 844.68 Cr | 1,149.41 Cr | 1,859.36 Cr | 6.40 Cr | 0.00 Cr | 11.66 Cr | 1,813.5010 Cr |
| 2022-03-31 | 184.71 Cr | 4,512.90 Cr | 1,925.81 Cr | 2,586.5329 Cr | 1,106.31 Cr | 921.60 Cr | 978.55 Cr | 1,595.64 Cr | 6.61 Cr | 0.00 Cr | -195.04 Cr | 1,641.6000 Cr |
| 2021-03-31 | 41.84 Cr | 3,713.45 Cr | 1,540.18 Cr | 2,173.2743 Cr | 849.21 Cr | 807.37 Cr | 782.18 Cr | 1,255.99 Cr | 117.07 Cr | 0.00 Cr | -202.43 Cr | 1,173.0981 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 766.6980 Cr | -694.8820 Cr | 10.9580 Cr | 195.0040 Cr | 207.3850 Cr | 596.3750 Cr | -571.6940 Cr | 501.5160 Cr | 60.0850 Cr | -36.3550 Cr | -20.5690 Cr |
| 2024-03-31 | 439.4140 Cr | -360.1600 Cr | 7.6640 Cr | 58.8380 Cr | 89.5430 Cr | 381.1000 Cr | -380.5760 Cr | 405.3100 Cr | 154.7780 Cr | -36.3060 Cr | -140.7300 Cr |
| 2023-03-31 | 663.6780 Cr | -96.4520 Cr | -519.4700 Cr | 451.8850 Cr | 47.5030 Cr | 181.7460 Cr | -211.7930 Cr | 663.9400 Cr | -47.0920 Cr | -18.6220 Cr | -2.6700 Cr |
| 2022-03-31 | 332.0541 Cr | -380.1149 Cr | 189.9971 Cr | -65.6528 Cr | 142.8775 Cr | 184.7134 Cr | -397.7069 Cr | 557.9983 Cr | 253.0410 Cr | -37.1713 Cr | -184.0266 Cr |
| 2021-03-31 | 432.4778 Cr | -277.1350 Cr | -299.3131 Cr | 161.1362 Cr | -144.0930 Cr | 41.8359 Cr | -271.3416 Cr | 704.3643 Cr | -71.9332 Cr | -24.7208 Cr | -345.8876 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 1,208.79 Cr | 425.07 Cr | 783.73 Cr | 0.6484 | 177.87 Cr | 112.64 Cr | 4.64 | 237.15 Cr | 0.0932 |
| 2025-03-31 | 1,197.43 Cr | 670.99 Cr | 526.44 Cr | 0.4396 | 188.86 Cr | 152.03 Cr | 6.27 | 285.03 Cr | 0.1270 |
| 2024-12-31 | 1,133.52 Cr | 435.68 Cr | 697.84 Cr | 0.6156 | 173.68 Cr | 117.60 Cr | 4.85 | 235.97 Cr | 0.1038 |
| 2024-09-30 | 956.52 Cr | 367.21 Cr | 589.32 Cr | 0.6161 | 150.80 Cr | 97.23 Cr | 4.01 | 206.57 Cr | 0.1017 |
| 2024-06-30 | 1,179.87 Cr | 700.92 Cr | 478.95 Cr | 0.4059 | 206.40 Cr | 134.65 Cr | 5.56 | 261.33 Cr | 0.1141 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 596.38 Cr | 2.61 Cr | 596.38 Cr | 942.22 Cr | 1,342.82 Cr | 3,115.48 Cr | 2,654.37 Cr | 6,252.56 Cr | 2,536.98 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 216.71 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -3,427.24 Cr |
| 2024-09-30 | 208.85 Cr | 9.71 Cr | 218.56 Cr | 726.73 Cr | 1,395.44 Cr | 2,605.34 Cr | 2,304.37 Cr | 5,432.70 Cr | 2,005.47 Cr |
| 2024-06-30 | -381.10 Cr | 762.20 Cr | 381.10 Cr | 0.00 Cr | 0.00 Cr | 381.10 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 386.39 Cr | 8.19 Cr | 386.39 Cr | 1,001.88 Cr | 1,300.55 Cr | 2,905.05 Cr | 2,115.63 Cr | 5,520.98 Cr | 2,295.44 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 117.60 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 97.23 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 134.65 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 129.65 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 125.65 Cr | 104.78 Cr | 0.00 Cr | 0.00 Cr | 104.78 Cr | 416.69 Cr | 311.91 Cr | 0.00 Cr | 104.78 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2015-03-23 | March 23, 15 | 10:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,609.00 | ₹3,860,441,520,000.00 | ₹1,626,288.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,050.50 | ₹1,606,220,184,500.00 | ₹63,569.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,530.90 | ₹1,195,015,450,500.00 | ₹135,292.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,300.70 | ₹1,082,646,847,453.00 | ₹954,623.00 |
| Mankind Pharma Limited | MANKIND | ₹2,588.90 | ₹1,068,589,227,622.00 | ₹92,714.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹1,036.15 | ₹1,042,605,214,500.00 | ₹296,469.00 |
| Lupin Limited | LUPIN | ₹2,040.60 | ₹932,054,253,000.00 | ₹325,910.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,506.50 | ₹658,384,672,500.00 | ₹126,076.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,100.80 | ₹639,346,841,600.00 | ₹870,057.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,100.20 | ₹592,678,540,200.00 | ₹402,431.00 |
| Laurus Labs Limited | LAURUSLABS | ₹893.00 | ₹482,063,725,000.00 | ₹396,445.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Cohance Lifesciences Limited | COHANCE | ₹982.00 | ₹375,680,801,856.00 | ₹57,880.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,309.10 | ₹332,123,906,400.00 | ₹70,482.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,555.50 | ₹319,273,948,000.00 | ₹14,183.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,681.60 | ₹263,331,833,600.00 | ₹78,315.00 |
| Piramal Enterprises Limited | PEL | ₹1,132.00 | ₹256,599,496,000.00 | ₹946,023.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,511.10 | ₹245,530,782,791.00 | ₹113,354.00 |
| Eris Lifesciences Limited | ERIS | ₹1,664.90 | ₹226,771,034,300.00 | ₹30,477.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,024.50 | ₹225,612,500,000.00 | ₹7,781.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹15,790.00 | ₹202,584,121,000.00 | ₹31,902.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹960.00 | ₹188,700,480,000.00 | ₹226,418.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,124.40 | ₹179,095,556,400.00 | ₹61,537.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,266.90 | ₹172,310,922,730.00 | ₹101,864.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹853.50 | ₹152,870,385,000.00 | ₹325,818.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹531.25 | ₹128,904,625,000.00 | ₹689,565.00 |
| Procter & Gamble Health Limited | PGHL | ₹6,267.00 | ₹104,028,439,800.00 | ₹5,131.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹936.70 | ₹84,895,902,062.00 | ₹207,949.00 |
| Strides Pharma Science Limited | STAR | ₹887.40 | ₹81,794,053,980.00 | ₹143,336.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹828.90 | ₹81,058,877,010.00 | ₹111,223.00 |
| FDC Limited | FDC | ₹465.80 | ₹75,836,898,000.00 | ₹37,634.00 |
| Suven Life Sciences Limited | SUVEN | ₹226.01 | ₹49,279,377,929.00 | ₹85,787.00 |
| Innova Captab Limited | INNOVACAP | ₹856.60 | ₹49,018,875,038.00 | ₹10,615.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹513.40 | ₹46,858,018,000.00 | ₹133,136.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹143.75 | ₹46,650,037,500.00 | ₹131,516.00 |
| Sequent Scientific Limited | SEQUENT | ₹183.98 | ₹46,056,633,300.00 | ₹295,810.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,385.30 | ₹39,450,476,700.00 | ₹8,145.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹365.95 | ₹36,696,734,100.00 | ₹21,786.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹707.00 | ₹35,858,403,700.00 | ₹36,027.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹504.15 | ₹35,495,084,070.00 | ₹8,735.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹118.86 | ₹34,888,619,220.00 | ₹11,214,307.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹676.15 | ₹32,558,650,950.00 | ₹52,292.00 |
| Hikal Limited | HIKAL | ₹260.75 | ₹32,150,735,750.00 | ₹115,051.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹53.52 | ₹29,326,498,080.00 | ₹1,745,659.00 |
| Indoco Remedies Limited | INDOCO | ₹294.30 | ₹27,148,556,970.00 | ₹140,867.00 |
| Alembic Limited | ALEMBICLTD | ₹104.84 | ₹26,921,024,775.00 | ₹231,892.00 |
Key Executives
Chief Technology Officer
Dr. P. V. Srinivas
Gender: Not Specified
Year Born: 1966
Chief Human Resources Officer
Mr. Atul Dhavle B.E.
Gender: male
Year Born: 1970
Chairman & MD
Dr. Krishna Prasad Chigurupati B.Sc.
Gender: Not Specified
Year Born: 1954
Company Secretary & Compliance Officer
Ms. Chaitanya Tummala
Gender: female
Year Born:
Chief Financial Officer
Mr. Mukesh Surana
Gender: male
Year Born: 1981
Joint MD, Chief Executive Officer & Additional Director
Dr. Kandiraju Venkata Sita Ram Rao B.Tech, M.E., Ph.D.
Gender: Not Specified
Year Born: 1963
President and Chief Strategy & Sustainability Officer
Mr. Sanjay Kumar
Gender: male
Year Born:
Whole-Time Director
Ms. Priyanka Chigurupati
Gender: female
Year Born:
Executive Director
Mr. Harsha Chigurupati BBA
Gender: male
Year Born: 1983
President & Head - Formulations Operations
Mr. Ramraj Rangarajulu
Gender: male
Year Born:
FAQs about Granules India Limited
Who is the CEO of the company?
The CEO is Kandiraju Venkata Sita Ram Rao M.E.,.
What is the current market price of the stock?
The current price is ₹534.35.
What is the 52-week price range?
The range is ₹422-628.
What is the market capitalization of the company?
The market capitalization is ₹12,965.68 crores.
What is the dividend yield?
The dividend yield is 0.28%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 27.05.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Granules India Limited (ISIN: INE101D01020) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹12,965.68 crores and an average daily volume of 1,507,414 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹1.5.